- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01799746
Mechanisms of Response to Diesel Exhaust in Subjects With Asthma
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The investigators will also characterize selected polymorphisms in glutathione-S-transferase (GST) genes that have been implicated in susceptibility to air pollutants. Outcome measures will include lung function, bronchial responsiveness to bronchodilator, exhaled nitric oxide, induced sputum for inflammatory markers (IL6 and IL8), and exhaled breath condensate for nitrite, 8-isoprostane, 20-HETE (20-hydroxyeicosatetraenoic acid), nitrotyrosine and pH.
In this pilot project, parallel studies are being carried out in the human exposure chambers at two NIEHS centers, the EOHSI-CEED (Environmental and Occupational Health Sciences Institute- Center for Environmental Exposure and Disease) and the Penn-CEET (University of Pennsylvania-Center of Excellence in Environmental Toxicology). The joint project will enable each center to validate research results in a second population and include new biomarkers of pulmonary inflammation. Each center will recruit, consent, and collect data on its own subjects. Only de-identified data will be shared between the centers.
Tipo di studio
Contatti e Sedi
Luoghi di studio
-
-
Pennsylvania
-
Philadephia, Pennsylvania, Stati Uniti, 19104
- Airways Biology Initiative at Penn Presbyterian Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Subject is an adult male or female between 18 and 55 years of age inclusive.
- Subject must have a prior history of a physician's diagnosis of asthma with reversible airway obstruction (shown by a greater than 12% increase in FEV1 following bronchodilator; or a positive methacholine challenge done following the screening visit. If methacholine challenge is required for qualification, a physician will be on-site for the test. Subject's asthma has been stable for the past six months with no change in asthma therapy.
- The subject has been a non-smoker for the past year and should have less than a 10-pack year history.
- Subject must be free of other significant pulmonary diseases (i.e., cystic fibrosis, tuberculosis, interstitial lung disease and bronchopulmonary dysplasia.
- The subject must be capable of and willing to provide written informed consent.
- The subject is able to understand and comply with protocol requirements and timetables, instructions and protocol-stated restrictions.
The subject has no significant DE exposure that would include occupations such as truck driver, heavy equipment operator and railroad maintenance.
-
Exclusion Criteria:
- As a result of the medical interview, physical examination or screening investigations, the physician responsible considers the volunteer unfit for the study.
- The subject has received an investigational drug or participated in any other research trial within 30 days or five half-lives or twice the duration of the biological effect of any drug (whichever is longer) prior to the current study.
- Oral steroids within the last 6 months.
- Less than 12% FEV1 response to bronchodilator or negative methacholine challenge.
- Hospital admission for asthma in past 6 months.
- The subject has a history of alcohol or drug abuse within the last 5 years.
- The subject has history of hepatitis B, hepatitis C or HIV virus.
- The subject has a history of cardiovascular disease including hypertension or says yes to one of the cardiovascular risk questions on the screening questionnaire.
- The subject has a history of diabetes.
- The subject is pregnant or lactating.
The subject has daily exposure to DE, i.e., trucking or heavy machine operators.
-
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
FEV1 response to bronchodilator, following DE compared with filtered air (primary outcome)
Lasso di tempo: Up to 3 weeks
|
Up to 3 weeks
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Exhaled nitric oxide
Lasso di tempo: Up to 3 weeks
|
Up to 3 weeks
|
|
8-isoprostane in exhaled breath condensate
Lasso di tempo: 1 year
|
1 year
|
|
Nitrite in exhaled breath condensate
Lasso di tempo: 1 year
|
1 year
|
|
pH in exhaled breath condensate
Lasso di tempo: 1 year
|
1 year
|
|
20-HETE(20-hydroxyeicosatetraenoic acid)levels in exhaled breath condensate
Lasso di tempo: 1 year
|
1 year
|
|
Cell differential in induced sputum
Lasso di tempo: 1 year
|
1 year
|
|
Glutathione-S-transferase (GST)polymorphisms
Lasso di tempo: Visit 1
|
Visit 1
|
|
Peak Flow
Lasso di tempo: Up to 3 weeks
|
Up to 3 weeks
|
|
Forced Vital Capacity (FVC)
Lasso di tempo: Up to 3 weeks
|
Up to 3 weeks
|
|
FEV1/FVC ratio
Lasso di tempo: Up to 3 weeks
|
Up to 3 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Reynold A Panettieri, Jr., MD, University of Pennsylvania
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 817330
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .